Cargando…
Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Tumor necrosis factor inhibitor (TNFi) has been applied in the treatment of ankylosing spondylitis (AS) for many years but still with an unmed need due to inefficacy or intolerance. Current treatment guideline recommended the use of IL-17 inhibitors over a second TNFi in patients with primary nonres...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sciendo
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524761/ https://www.ncbi.nlm.nih.gov/pubmed/36465082 http://dx.doi.org/10.2478/rir-2020-0004 |